{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:12:28Z","timestamp":1790802748165,"version":"4.1.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"DOI":"10.1093\/ibd\/izy238","type":"journal-article","created":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T14:30:52Z","timestamp":1531751452000},"page":"74-77","source":"Crossref","is-referenced-by-count":29,"title":["Defining Failure of Medical Therapy for Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"25","author":[{"given":"Neil","family":"Volk","sequence":"first","affiliation":[{"name":"Dartmouth-Hitchcock Inflammatory Bowel Disease Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey A","family":"Siegel","sequence":"additional","affiliation":[{"name":"Dartmouth-Hitchcock Inflammatory Bowel Disease Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,7,16]]},"reference":[{"key":"key\n\t\t\t\t2018121208435540900_CIT0001","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/jama.1932.02740680019005","article-title":"Oppenheimer regional ileitis","volume":"99","author":"Crohn","year":"1932","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0002","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2036.2009.04027.x","article-title":"Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials","volume":"30","author":"Lichtenstein","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0003","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0004","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa067594","article-title":"Certolizumab pegol for the treatment of Crohn\u2019s disease","volume":"357","author":"Sandborn","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0005","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0006","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1002\/ibd.20600","article-title":"How often do IBD patients require resection of their intestine","volume":"14","author":"Hancock","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0007","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/gut.2010.234617","article-title":"Surgery for adult Crohn\u2019s disease: what is the actual risk","volume":"60","author":"Bouguen","year":"2011","journal-title":"Gut"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0008","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s10350-004-6296-8","article-title":"Remicade does not abolish the need for surgery in fistulizing Crohn\u2019s disease","volume":"45","author":"Poritz","year":"2002","journal-title":"Dis Colon Rectum"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0009","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study","volume":"121","author":"Faubion","year":"2001","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/SLA.0b013e3181e61df5","article-title":"Trends in surgery for Crohn\u02bcs disease in the era of infliximab","volume":"252","author":"Jones","year":"2010","journal-title":"Ann Surg"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0011","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1053\/j.gastro.2012.01.035","article-title":"Adalimumab induces and maintains mucosal healing in patients with Crohn\u2019s disease: data from the EXTEND trial","volume":"142","author":"Rutgeerts","year":"2012","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0012","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/gut.2009.183095","article-title":"Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis","volume":"59","author":"Seow","year":"2010","journal-title":"Gut"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0013","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn\u2019s disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0014","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2010.135111","article-title":"The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept","volume":"70","author":"Jamnitski","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0015","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.cgh.2016.05.010","article-title":"Appropriateness of testing for anti-tumor necrosis factor agent and antibody concentrations, and interpretation of results","volume":"14","author":"Melmed","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0016","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/01.MIB.0000195391.49762.89","article-title":"Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health","volume":"12","author":"Farrokhyar","year":"2006","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0017","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.crohns.2014.02.027","article-title":"Bile acid malabsorption assessed by 7 alpha-hydroxy-4-cholesten-3-one in pediatric inflammatory bowel disease: correlation to clinical and laboratory findings","volume":"8","author":"Gothe","year":"2014","journal-title":"J Crohns Colitis"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0018","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/00365520410007971","article-title":"Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease","volume":"39","author":"R\u00f8seth","year":"2004","journal-title":"Scand J Gastroenterol"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0019","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ibd.20312","article-title":"Crohn\u2019s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn\u2019s Disease Activity Index and endoscopic findings","volume":"14","author":"Sipponen","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0020","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/MPG.0b013e31810e75a9","article-title":"Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease","volume":"45","author":"Fagerberg","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0021","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/01.MIB.0000442681.85545.31","article-title":"Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease","volume":"20","author":"Kopylov","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0022","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/ibd.20986","article-title":"Ulcerative colitis: correlation of the Rachmilewitz Endoscopic Activity Index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes","volume":"15","author":"Schoepfer","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0023","first-page":"753","article-title":"Mikami M. Calprotectin (S100A8\/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity","volume":"266","author":"Satoru","year":"2003","journal-title":"Biol Pharm Bull"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0024","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00003072-199904000-00005","article-title":"Tc-99m dextran and Tc-99m HIG findings in patients with ulcerative colitis","volume":"24","author":"Sarikaya","year":"1999","journal-title":"Clin Nucl Med"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0025","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.MIB.0000173271.18319.53","article-title":"Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease","volume":"11","author":"Solem","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0026","article-title":"Development and validation of a multi-marker serum test for the assessment of mucosal healing in Crohn\u2019s disease patients","author":"Kelly","year":"","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0027","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1053\/j.gastro.2014.08.035","article-title":"Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis","volume":"147","author":"Adedokun","year":"2014","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0028","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0029","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00228-009-0718-4","article-title":"Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis","volume":"65","author":"Fasanmade","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0030","doi-asserted-by":"crossref","first-page":"297","DOI":"10.5414\/CPP48297","article-title":"Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis","volume":"48","author":"Fasanmade","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0031","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(13)60128-6","article-title":"157 fecal loss of infliximab as a cause of lack of response in severe inflammatory bowel disease","volume":"144","author":"Brandse","year":"2013","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0032","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jps.20178","article-title":"Antibody pharmacokinetics and pharmacodynamics","volume":"93","author":"Lobo","year":"2004","journal-title":"J Pharm Sci"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0033","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0034","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1080\/00365520802699278","article-title":"Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies","volume":"44","author":"Bendtzen","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0035","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0036","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/gut.36.6.897","article-title":"Significance of systemic endotoxaemia in inflammatory bowel disease","volume":"36","author":"Gardiner","year":"1995","journal-title":"Gut"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0037","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1080\/00365520701409035","article-title":"Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis","volume":"42","author":"Olsen","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0038","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/apt.13268","article-title":"Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal","volume":"42","author":"Ben-Horin","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0039","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/00365520150218084","article-title":"Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease","volume":"36","author":"Belaiche","year":"2001","journal-title":"Scand J Gastroenterol"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0040","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/gast.2002.32420","article-title":"6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease","volume":"122","author":"Dubinsky","year":"2002","journal-title":"Gastroenterology"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0041","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/gut.39.3.401","article-title":"6-Mercaptopurine metabolism in Crohn\u2019s disease: correlation with efficacy and toxicity","volume":"39","author":"Cuffari","year":"1996","journal-title":"Gut"},{"key":"key\n\t\t\t\t2018121208435540900_CIT0042","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/ajg.2016.236","article-title":"The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn\u2019s disease: results from the US VICTORY Consortium","volume":"111","author":"Dulai","year":"2016","journal-title":"Am J Gastroenterol"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/25\/1\/74\/27096699\/izy238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T21:54:40Z","timestamp":1571608480000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/25\/1\/74\/5054534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,16]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,7,16]]},"published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izy238","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,1]]},"published":{"date-parts":[[2018,7,16]]}}}